

DETAILED ACTION

Claims 13-15 and 20-23 are currently pending in the instant application, appear allowable over the prior art and have been renumbered as claims 1-7. Applicants' amendment has overcome the objection to the claims as containing non-elected subject matter and the informality rejection of claim 13. The provisional obvious type double patenting rejection is withdrawn as the instant application has the earliest filing date.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Sylvia A. Ayler on 15 January 2009.

The application has been amended as follows:

1. In the Specification, delete the paragraph on page 13, lines 13-29 and replace it with the following (this amendment is after the changes in the specification amendment filed 14 January 2009 and includes strike-through and underlining to show changes):

"This invention is also concerned with compositions and methods of treating ocular hypertension or glaucoma by administering to a patient in need thereof one of the compounds of formula I in combination with a β -adrenergic blocking agent such as timolol, betaxolol, levobetaxolol, carteolol, levobunolol, a parasymphathomimetic agent such as epinephrine, ~~ipridine~~ IOPIDINE (Apraclonidine), brimonidine, clonidine, para-aminoclonidine, carbonic anhydrase inhibitor such as dorzolamide, acetazolamide,

metazolamide or brinzolamide, an EP4 agonist (such as those disclosed in WO 02/24647, WO 02/42268, EP I 114816, WO 01/46140 and WO 01/72268), a prostaglandin such as latanoprost, travaprost, unoprostone, (Reeseula®) RESCULA (Unoprostone isopropyl), S 1033 (compounds set forth in US Patent Nos. 5,889,052; 5,296,504; 5,422,368; and 5,151,444); a hypotensive lipid such as lumigan LUMIGAN (Bimatoprost) and the compounds set forth in US Patent No. 5,352,708; a neuroprotectant disclosed in US Patent No. 4,690,931, particularly eliprodil and R-eliprodil as set forth in WO 94/13275, including memantine; or an agonist of 5-HT₂ receptors as set forth in PCT/US00/31247, particularly 1-(2-aminopropyl)-3-methyl-1H-imidazol-6-ol fumarate and 2-(3-chloro-6-methoxy-indazol-1-yl)-1-methyl-ethylamine. An example of a hypotensive lipid (the carboxylic acid group on the a-chain link of the basic prostaglandin structure is replaced with electrochemically neutral substituents) is that in which the carboxylic acid group is replaced with a C i-6 alkoxy group such as OCH₃ (PGF_{2a} I-OCH₃), or a hydroxy group (PGF_{2a} I-OH)."









2. In the claims, please amend claim 15 as follows: (Claim 15 is reproduced below as found in the amendment filed 14 January 2009 for clarity as the facsimile was not clear).













15. (Currently amended)











A compound of Table 1 through 4 which is:

Table 1



R1	R2	R3
H	Phenyl	
H	Phenyl	
H	Phenyl	
H	Phenyl	
H	Phenyl	
H	Phenyl	
H	Phenyl	
OMe	Phenyl	

R1	R2	R3
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	
OMe	Phenyl	

OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	
OMe	Isopropyl	




OMe	Isopropyl	
-----	-----------	---

Table 2



R2	R3	R2	R3

Table 4



R2	R3	R2	R3

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

3. Amend claim 23 as follows:

23. (Currently Amended) A composition according to Claim 22 wherein the beta-adrenergic blocking agent is timolol, betaxolol, levobetaxolol, carteolol, or levobunolol; the parasympathomimetic agent is pilocarpine; the sympathomimetic agent is epinephrine, brimonidine, ~~ipidine~~ apraclonidine, clonidine, or para-aminoclonidine, the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, metazolamide or brinzolamide; the prostaglandin is latanoprost, travaprostone ~~or (Rescula®)~~ or unoprostone, the hypotensive lipid is ~~lunigan bimatoprost~~, the neuroprotectant is eliprodil, R-eliprodil or memantine; and the 5-HT₂ receptor agonist is 1-(2-aminopropyl)-3-methyl-1H-imidazol-6-yl fumarate or 2-(3-chloro-6-methoxy-indazol-1-yl)-1-methylethylamine.

Reasons for Allowance

The following is an examiner's statement of reasons for allowance. This invention relates to products of the formula I. The novel and nonobvious aspect of this invention involves the substituent Q, R₂ and R₃. The closest prior art of record fails to teach or suggest applicants' instantly claimed invention.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rebecca L. Anderson whose telephone number is (571) 272-0696. Mrs. Anderson can normally be reached Monday through Friday from 6:00am until 2:30pm.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

*/Rebecca Anderson/
Primary Examiner, AU 1626*

Rebecca Anderson
Primary Examiner
Art Unit 1626, Group 1620
Technology Center 1600

21 January 2009